Tempus AI, Inc. Class A (TEM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Tempus AI, Inc. Class A stock $52.58, price $64.76, that is 18.8% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Tempus AI, Inc. Class A
TEM · USExpensive (fair value 19% below the price), weak company and price moving sideways: meets none of the 3 rules.
Main risks:
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
29‑month range $24.96 – $103.25 · fair‑value band $39.43 – $65.72 · the $64.76 price screens above the $52.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether Tempus AI, Inc. Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Tempus AI, Inc. operates as a healthcare technology company in the United States.
Show moreShow less
It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.
Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.
It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia.
The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Stock analysis
Tempus AI, Inc. Class A (TEM) currently trades at $64.76, while our estimate is $52.58, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $39.43 (bear) to $65.72 (bull), the price of $64.76 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tempus AI, Inc. Class A reported revenue of $1.3B in FY2025 versus $258M in FY2021, a compound +49.0%/yr. Reported net income was −$245M in FY2025.
Key figures
Market cap $10.9B Large · P/S ratio 8.51 · EPS (TTM) $−1.06 · Net margin −12.5% · Return on equity −37.6% · Return on assets (EBIT) −41.6% (5-year average) · Operating margin −13.8% · Revenue (TTM) $1.5B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 24% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −19%, TEM screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 9 officers or directors sold shares worth $125.3M and none bought.
- SaleDavid R EpsteinDirector7× since Dec 1, 2025: 2,110 shares, avg. $59.63$125,825Nov 2, 202610b5-1 plan
- SaleRyan FukushimaCEO, Data14× since Nov 18, 2025: 217,350 shares, avg. $55.97$12.2MNov 2, 2026
- SaleEric P LefkofskyCEO and Chairman, Director, 10% owner17× since Nov 18, 2025: 2,881,592 shares, avg. $62.05$178.8MOct 27, 2026
- SaleThomas Edward SchoenherrCEO, Diagnostics3× since May 19, 2026: 29,175 shares, avg. $64.22$1.9MSep 25, 2026
- SaleRyan M BartolucciChief Accounting Officer5× since Nov 18, 2025: 22,089 shares, avg. $59.26$1.3MSep 17, 2026
- SaleAndrew PolovinEVP, Chief Legal Officer6× since Nov 18, 2025: 85,287 shares, avg. $58.98$5.0MSep 17, 2026
- SaleJennifer A DoudnaDirector4× since Dec 1, 2025: 5,275 shares, avg. $60.21$317,611Sep 1, 202610b5-1 plan
- SaleNadja WestDirector2× since Aug 14, 2026: 6,000 shares, avg. $61.45$368,700Aug 28, 202610b5-1 plan
- SaleJames William RogersChief Financial Officer7× since Nov 18, 2025: 119,945 shares, avg. $57.69$6.9MAug 19, 2026
- SaleErik PhelpsEVP, Chief Admin. Officer3× since Nov 18, 2025: 14,299 shares, avg. $61.67$881,800Feb 19, 2026
Plus 1 more entries from the last 12 months.
Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
TEM screens overvalued: fair value 19% below the price. Compare with Veeva Systems Inc →
Recent news
- Tempus AI And 2 More AI Healthcare Stocks
- Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
- Tempus AI (TEM) Surged on Data Business Momentum and MRD Testing Expansion
- SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
Compare Tempus AI, Inc. Class A with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks
Valuation Multiplesvs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Doximity, Inc DOCS | $32.77 | $36.67 | +12% | vs TEM |
| Veeva Systems Inc VEEV | $299.28 | $329.21 | +10% | vs TEM |
| HealthEquity, Inc HQY | $104.58 | $115.04 | +10% | vs TEM |
| Waystar Holding WAY | $28.11 | $29.10 | +4% | vs TEM |
| HeartFlow, Inc HTFL | $46.86 | $30.50 | −35% | vs TEM |
| Hinge Health, Inc HNGE | $121.29 | $51.25 | −58% | vs TEM |
| Pro Medicus Limited PME | A$201.65 | A$82.80 | −59% | vs TEM |
| BrightSpring Health Services, Inc BTSG | $71.37 | $25.72 | −64% | vs TEM |
| XtalPi Holdings 2228 | HK$5.53 | HK$1.53 | −72% | vs TEM |
| Privia Health Group PRVA | $25.26 | $5.52 | −78% | vs TEM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Tempus AI, Inc. Class A (TEM) overvalued or undervalued?
What is the fair value of TEM?
What is the quality score of TEM?
What is the price target for Tempus AI, Inc. Class A (TEM)?
What is the Tempus AI, Inc. Class A stock forecast for 2026?
What is the revenue of Tempus AI, Inc. Class A (TEM)?
What is the intrinsic value of Tempus AI, Inc. Class A (TEM)?
Is Tempus AI, Inc. Class A stock overvalued or undervalued in 2026?
Is fair value the same as the market price of TEM?
How much is Tempus AI, Inc. Class A worth?
What do the bullish and bearish scenarios say about TEM?
How solid is the balance sheet of Tempus AI, Inc. Class A (TEM)?
How far is TEM from its 52-week high?
Which stocks are comparable to Tempus AI, Inc. Class A?
Is Tempus AI, Inc. Class A stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Tempus AI, Inc. Class A (TEM)?
What should I pay attention to with Tempus AI, Inc. Class A right now?
Key figures of Tempus AI, Inc. Class A
How large is the market capitalisation of Tempus AI, Inc. Class A (TEM)?
What is the P/S ratio of Tempus AI, Inc. Class A (TEM)?
What are the earnings per share of Tempus AI, Inc. Class A (TEM)?
What is the net margin of Tempus AI, Inc. Class A (TEM)?
What is the return on equity of Tempus AI, Inc. Class A (TEM)?
What is the EBIT return on assets of Tempus AI, Inc. Class A (TEM)?
What is the operating margin of Tempus AI, Inc. Class A (TEM)?
How fast is revenue growing at Tempus AI, Inc. Class A (TEM)?
How much free cash flow does Tempus AI, Inc. Class A (TEM) generate?
How much net debt does Tempus AI, Inc. Class A (TEM) carry?
Watch Tempus AI, Inc. Class A in the live analysis
One click puts Tempus AI, Inc. Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.